

## Dexmedetomidine versus Ketamine-Propofol for Sedation of Obese Patients Undergoing Upper Gastrointestinal Endoscopy

## Chesis

Submitted for Partial Fulfillment of Master Degree in Anesthesiology,

Intensive care and Pain Management

By

#### **Ola Nasser Hussain Zaher**

M.B.B.Ch, Faculty of Medicine, Ain Shams University.

## Under Supervision of

### **Dr. Reem Hamdy El Kabarity**

Professor of Anesthesia, Intensive care and Pain Management Faculty of Medicine-Ain Shams University

### Dr. Rania Magdy Mohamed Ali

Assistant Professor of Anesthesia, Intensive care and Pain Management Faculty of Medicine-Ain Shams University

#### **Dr. Mohamed Moien Mohamed**

Lecturer of Anesthesia, Intensive care and Pain Management Faculty of Medicine-Ain Shams University

> Faculty of Medicine Ain Shams University 2019



سورة البقرة الآية: ٣٢



Praise to Allah, the Merciful, the compassion for all gifts, I have been offered one of these gifts is the accomplishment of this work.

Words can never express my thanks to **Dr. Reem Hamdy El Kabarity** Professor of Anesthesia, Intensive care and Pain

Management Who always gave much of her time, unlimited help, effort and sincere advice for the perfection of the study.

I am deeply grateful to **Dr. Rania Magdy Mohamed Ali**Assistant Professor of Anesthesia, Intensive care and Pain Management
For her close supervision, effort and sincere advice for the perfection of the study.

Also, I would like to thank **Dr. Mohamed Moien**Mohamed Lecturer of Anesthesia, Intensive care and Pain

Management For his assistance, unlimited help, kindness and his appreciation to all what passed during accomplishing this study.

Finally, I want to thank my family for giving me the continuous motivation to accomplish this work.

Ola Nasser Hussain Zaher

## **Contents**

Subject	Page No.
Contents	I
List of Tables	ii
List of Figures	iii
List of Abbreviations	iiivi
Abstract	vi
Introduction	1
Aim of the Study	5
Review of Literature	6
> Obesity and anesthetic considerations	6
> Procedural sedation	35
> Pharmacology of Dexmedetomidine	44
Subjects & Methods	88
Results	94
Discussion	101
Conclusion and Recommendations	108
Summary	110
References	110
اللخص العربي	113

## **List of Tables**

	<b>S</b> 4-	
Table No.	Oitle	Page No.

Table (1): World Health Organization classification of obesity
Table (2): Multiple strategies available to anesthetists to reduce the risk of aspiration in obese patients
<b>Table (3):</b> The STOP BANG screening questionnaire for obstructive sleep apnea. One point is scored for each positive feature; a score ≥ 5 is a significant risk
Table (4): The ASA defines three levels of sedation.    35
Table (5): Selected indications for procedural sedation         36
<b>Table (6):</b> Ramsay scale         39
Table (7): Incidence of Adverse Events per 1, 000 Procedural Sedations
Table (8): The Modified Aldrete Score)    91
Table (9): satisfaction score   92
Table (10): Comparison of the demographic data between the two groups.       94
Table (11): Comparison of time to achieve RSS 3-4 between both groups
Table (12): Comparison between the two groups regarding the heart rate.       96
Table (13): Comparison between the two groups regarding mean arterial blood pressure.         97
Table (14): Comparison between the two groups regarding oxygen saturation%
Table (15): Comparison between the two groups regarding the recovery time.       98
<b>Table (16):</b> Comparison between the two groups regarding VAS.         99
Table (17): Comparison between the two groups regarding the occurrence of complications.         99
Table (18): Comparison between the two groups regarding patient's satisfaction.         100

## **List of Figures**

Figure	? No.	itle	Page No.
Fig(1): (	Chemical structure of dex	medetomidine	45
Fig(2): (	G-Protein-coupled α2-AR		47
Fig(3): (	Chemical structure of Pro	pofol	57
Fig(4):A	=	el describes the drug's	-
Fig(5):S	$((\alpha 1)2(\beta 2)2(\gamma 2))$ which subunits that form the channel pore, the two G $\alpha 1$ and $\beta 2$ interfaces,	a GABAA receptor illustrates the five corprotein, the chloride (CABA active binding site and the benzodiazepine	mbined l-) ion s at the (BDZ)
Fig(6):S		etamine and Skeletal f	
Fig. (7):		ps according to time to a	
Fig. (8):	_	groups according to hea	
Fig. (9):		oups according to mean	

## **List of Abbreviations**

ASV .....: Adaptive support ventilation

BMI ...... Body mass index

**CBC.....**: Complete blood picture

**CPAP** .....: Continuous positive airway pressure

CT scan .....: Computed tomography scan

CVS.....: Cardiovascular system

**DVT....**: Deep venous thrombosis

**ERCP** ...... Endoscopic retrograde cholangiopancreatography

ETT ..... Endotracheal tube

FRC.....: Functional residual capacity

GA ...... General anesthesia

GABA......Gamma-aminobutyric acid

GERD......Gastroesophageal reflux disease

GI ...... Gastrointesinal

HR ..... Heart rate

ICU.....: Intensive care unit

**Ketofol** ...... Ketamine-propofol combination

MABP ...... Mean arterial blood pressure

MAS ...... Modified aldrete score

MRI...... Magnetic resonance imaging

**NAFLD** ...... Nonalcoholic fatty liver disease

#### List of Abbreviations

NASH.....: Nonalcoholic steatohepatitis

NAVA...... Neurally adjusted ventilatory assist

**NMDA Receptor**: N-Methyl-d-aspartate receptor

NSAIDS ...... Nonsteroidal anti-inflammatory drugs

**OFA....:** Opioid-free anesthesia

**OHS.....**: Obesity hypoventilation syndrome

**OR** ...... Operating room

**OSA....:** Obstructive sleep apnea

PAV....: Proportional assist ventilation

PCS......Patient-controlled sedation

**PSV.....**: Pressure support ventilation

VTE...... Venous thromboembolism

#### **Abstract**

Background: Gastrointestinal endoscopy is an uncomfortable and stressful procedure for most patients. Conscious sedation is a common strategy for improving patient comfort during this procedure. Benzodiazepines (gamma-aminobutyric acid (GABA) agonists) such as midazolam have been used for sedation of patients undergoing gastrointestinal endoscopy. The effective dose ranges of such agents differ considerably among patients, making it difficult to achieve stable sedation. Also obesity is a significant health problem that has assumed epidemic proportions. As a result, the number of obese patients requiring endoscopy is increasing. It is relatively unknown how safe the current practices of sedation for endoscopic procedures are in bariatric patients. Therefore, special consideration should be given to these patients.

**Aim of the Work:** To compare the sedative properties and haemodynamic and respiratory effects of Dexmedetomidine and a Ketamine-Propofol combination (ketofol) in obese patients undergoing Upper GI Endoscopy.

**Patients and Methods:** This study was conducted in the endoscopy unit of Ain Shams University Hospital after obtaining approval from the Research Ethical Committee of Ain Shams University. A prospective, randomized controlled clinical trial was found to be the most suitable design in order to achieve the study objectives. Cases were divided into 2 groups using computer generated random list of numbers in sealed opaque envelopes.

**Results:** We found that ketamine-propofol infusion (1:3) is a better sedation regimen for upper gastrointestinal endoscopy compared to dexmedetomidine as lesser time is taken to achieve optimal sedation, with no hemodynamic unstability or postprocedure complications. **Conclusion:** In this study, we compared a group of 40 upper GIT endoscopy obese patients (BMI 30-40) who received procedural sedation with either Dexmedetomidine or propofol-ketamine combination, we found that ketamine-propofol infusion (1:3) is a better sedation regimen for upper gastrointestinal endoscopy compared to dexmedetomidine as lesser time is taken to achieve optimal sedation, with no hemodynamic unstability or post procedure complications.

**Keywords:** Dexmedetomidine - Ketamine-Propofol - Upper Gastrointestinal Endoscopy

## Introduction

Gastrointestinal endoscopy is an uncomfortable and stressful procedure for most patients. Conscious sedation is a common strategy for improving patient comfort during this Benzodiazepines (gamma-aminobutyric procedure. (GABA) agonists) such as midazolam have been used for sedation of patients undergoing gastrointestinal endoscopy. The effective dose ranges of such agents differ considerably among patients, making it difficult to achieve stable sedation. (Nishizawa et al., 2017)

Obesity is a significant health problem that has assumed epidemic proportions. As a result, the number of obese patients requiring endoscopy is increasing. Morbid obesity can result in pulmonary hypertension, obstructive sleep apnea, and restrictive lung disease. It is relatively unknown how safe the current practices of sedation for endoscopic procedures are in bariatric patients. Therefore, special consideration should be given to these patients, and endoscopists need to be aware of challenges that may be present while performing endoscopic procedures in obese patients. (Triantafillidis et al., 2013)

Propofol, a phenolic derivative, has sedative and hypnotic effects that are mediated by the GABA receptor. It has no analgesic action. It is highly lipophilic, and thus can rapidly cross the blood-brain barrier, resulting in an early onset of action. The most important disadvantage of propofol is the risk of rapidly induced deep sedation, with the causing respiratory possibility of and cardiovascular depression. On the other hand, recent meta-analysis shows that the use of propofol as a sedative during gastrointestinal endoscopy provides a shorter recovery time and better sedation than traditional sedative agents without causing an increase in cardiopulmonary complications. (Nishizawa et al., 2017)

Ketamine-Propofol is a combination of ketamine and propofol. Ketamine is an N-methyl D-aspartate receptor antagonist with the properties of sedation, analgesia, and amnesia without causing respiratory depression. Its drawbacks are vomiting and recovery agitation. Propofol has rapid onset and fast recovery time from sedation but is inadequate as a sole agent in semi-invasive procedures as it lacks analgesic properties. It induces cardiovascular depression and hypotension in a dose-dependent manner and

also causes apnea. The untoward effects of ketamine and propofol are reduced and balanced by each other as a combination (ketofol) producing synergistic, smoother sedation with a favorable hemodynamic profile. Ketofol has been used in proportions of 1:1–1:10 (ketamine:propofol), and it has been shown that 1:3 has a better advantage in procedural sedation. Ketofol has been used in ECT, pediatric cardiac catheterization, ERCP, dressings for burns, short procedural sedation for lumbar puncture, and bone marrow aspiration in various combinations and has shown adequate sedation with balanced hemodynamic parameters. (*Sruthi et al.*, 2018)

Dexmedetomidine is an alpha-2 adrenergic receptor agonist and has an eight times higher than clonidine for alpha-2 adrenergic receptors. It has sedative, anxiolytic and analgesic properties that produce cardiorespiratory stability at the therapeutic doses. The use of dexmedetomidine may be expanded as an intravenous drug in the medical procedures. Dexmedetomidine is approved by the United States Food and Drug Administration for short-term sedation (< 24 h) in adult patients in the intensive care unit (ICU). It also has been used in combination with other sedoanalgesic drugs during painful

procedures. Several reports in the literature have been confirmed about its effective use in various gastrointestinal endoscopic (GIE) procedures, although further controlled studies are needed to reinforce its use. This review is aimed to define the role of dexmedetomidine in GIE procedures. (*Amornyotin*, 2016)

## **Aim of the Study**

This study is to compare the sedative properties and haemodynamic and respiratory effects of Dexmedetomidine and a Ketamine-Propofol combination (ketofol) in obese patients undergoing Upper Gastrointestinal Endoscopy.

# Review of Literature Obesity and anesthetic considerations Introduction

Obesity is a medical condition with a multi-system disorder, particularly involving the respiratory and cardiovascular systems; therefore, a multidisciplinary anesthetic approach is required. (*Lotia and Bellamy, 2008*), the WHO organization classified obesity as shown in (**Table1**).

**Table (1): World Health Organization classification of obesity** 

Body mass index; kg.m2	Classification
< 18.5	Underweight
18.5–24.9	Normal
25.0–29.9	Overweight
30.0–34.9	Obese 1
35.0–39.9	Obese 2
> 40.0	Obese 3 (previously 'morbid obesity')

(Nightingale et al., 2015)

#### **Prevelance of obesity**

A study in 2016 in Egypt showed that out of 3000 participants, with the mean age of  $22.4 \pm 2.8$  years there were